Greater Manchester Medicines Management Group

Greater Manchester Clinical Standards Board

NHS

News

<< Back

News Summary

From this page you will be able to access a summary of additions or changes to the GMMMG website during September 2019

September 2019

 

High Cost Drugs Subgroup

13.9.19

Following approval at the September Directors of Commissioning meeting  Dibotermin alfa (InductOs®) for the treatment of non-union fracture CCG commissioning of Dibotermin alfa is recommended only for use by non-union specialists at GM trauma centres (i.e. MFT-ORC and SRFT) and if used in line with this GMMMG statement.

Pathways and Guidelines Development Subgroup (PaGDSG)

10.9.19

On behalf of the GMMMG Pathways and Guidelines Development Subgroup, a Greater Manchester-wide Shared Care Protocol for First generation (Typical) antipsychotic depots in adults is in development. We now seek comments on this draft. This consultation period is open until 5pm Tuesday 22nd October.

10.9.19

On behalf of the GMMMG Pathways and Guidelines Development Subgroup, a Greater Manchester-wide Shared Care Protocol for Riluzole for ALS is in development. We now seek comments on this draft. This consultation period is open until 5pm Tuesday 22nd October.

Formulary and Managed Entry Subgroup (FMESG)

9.9.19

The following FMESG actions for August 2019 have been proposed and will be sent to CSB for support. We now seek comments on these proposals.  This consultation is open until 5pm on Monday 21st October 2019

<< Back

Line

TERMS AND CONDITIONS    |    CONTACT US    |    ABOUT US    |    ARCHIVE

RSS Feed
 
spacer